Aegerion Pharmaceuticals, Inc.
) Juxtapid was approved in Canada as an adjunct to a low-fat diet
and other lipid-lowering drugs, with or without low-density
lipoprotein (LDL) apheresis, for the reduction of LDL cholesterol
(LDL-C) in adults suffering from homozygous familial
hypercholesterolemia (HoFH). Aegerion gained over 5.5% on the
AEGERION PHARMA (AEGR): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
ISIS PHARMACEUT (ISIS): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.
We note that Juxtapid was launched in the U.S. in late Jan 2013
for the HoFH indication. Moreover, Aegerion gained EU approval
for the drug in Jul 2013 under the brand name Lojuxta. Juxtapid
was also approved in Mexico last month for the same indication.
Juxtapid's label carries a boxed warning regarding the risk of
liver toxicity. Given the risk, Juxtapid is available through a
limited program under the Risk Evaluation and Mitigation Strategy
(REMS). This program is called the Juxtapid REMS program.
We are encouraged by the approval of Juxtapid in Canada. Aegerion
is slowly recovering from the blow it received last month.
Aegerion's share price fell over 12.1% on Jan 10, 2014, on the
disclosure that the Department of Justice has issued a subpoena
asking the company to provide documents related to the marketing
and sale of Juxtapid.
Moreover, Juxtapid targets the highly competitive and crowded
cardiovascular disease market. We note that
Isis Pharmaceuticals Inc.
) Kynamro is also available in the U.S. HoFH market since the
first quarter of 2013. We expect investor focus to remain on the
HoFH drug going forward.
Aegerion, a biopharma stock, currently carries a Zacks Rank #4
(Sell). Some better-ranked stocks in the same sector include
). Actelion holds a Zacks Rank #1 (Strong Buy).